News
Access to prescription drug coverage improves myeloma survival
Patients with myeloma with outpatient prescription drug coverage were more likely to receive oral targeted agents instead of parenteral...
Clarithromycin Plus Bortezomib May Be Ineffective, Toxic in Multiple Myeloma
Clarithromycin plus bortezomib does not confer any additional efficacy and is a toxic combination among patients with multiple myeloma (MM),...
Leukogene Therapeutics receives funding to develop compound for resistant multiple myeloma
A $2 million phase 2 Small Business Technology Transfer (STTR) grant to optimize a promising new compound that has shown efficacy in preclinical...
UK panel rejects CAR T-cell therapy due to cost
An independent body that offers guidance to improve health and social care in England recommended against the use of axicabtagene ciloleucel, one of...
Could a Blood Test Help Clinicians Diagnose Multiple Myeloma Earlier?
There may be a way to detect multiple myeloma (MM) earlier — effectively shortening the longer diagnostic interval that is typically associated with...
Expert Reflects on “Incredible” Data Seen With bb2121 in Heavily Pretreated Myeloma
The deep and durable phase I responses seen with the anti-BCMA chimeric antigen receptor (CAR) T-cell therapy bb2121 in patients with...
Two CAR T-Cell Therapies Greenlighted in Europe
The European Commission has approved the use of Novartis’s tisagenlecleucel (Kymriah) and Gilead’s axicabtagene ciloleucel (Yescarta), two chimeric...
An Integrative Multiomics Approach to Multiple Myeloma
When practicing precision oncology for multiple myeloma, clinicians currently match specific DNA mutations to the optimal targeted therapy. However,...
Research Review: Multiple Myeloma – Issue 27
Issue 27 of Multiple Myeloma Research Review Highlights include: Low dose lenalidomide + dexamethasone in newly diagnosed POEMS syndrome. Loss of...
CRISPR Modified CAR T-Cells Bolster Immuno Oncology Arsena
CRISPR (pronounced “crisper”) and CAR T-cell therapy are genetic technologies that have generated continued excitement during the last several...
PVX-410 Vaccine May Delay Disease Progression of Smoldering Multiple Myeloma
Previous studies have suggested that the progression of SMM to symptomatic multiple myeloma (MM) may be mediated by the immune system; reinforcing...
Once-Weekly Carfilzomib Submitted for FDA Approval in Myeloma
FDA approval is being sought for a once-weekly dosing option of carfilzomib (Kyprolis) for use in combination with dexamethasone as a treatment for...